CytRx Begins Global Phase 2b Trial Of Aldoxorubicin - Quick Facts

(RTTNews) - CytRx Corp.(CYTR) Tuesday said it has begun its Phase 2b clinical trial evaluating aldoxorubicin compared to topotecan in patients with extensive-stage small cell lung cancer or SCLC, who have relapsed or were refractory to prior chemotherapy. Aldoxorubicin is the company's modified version of the chemotherapeutic agent, doxorubicin and the FDA has granted it orphan drug designation for the treatment of SCLC. The open-label Phase 2b clinical study is expected to enroll about 132 patients and they will receive either aldoxorubicin or topotecan. The primary endpoint of the study is progression-free survival or PFS and the secondary endpoints are overall survival, overall response rates and the safety of aldoxorubicin compared to topotecan in this population. Patient enrollment is expected to be completed in 2015 and PFS data are anticipated by mid-2016.